J. Schiller

Journal of Clinical Oncology · 2002–2014

A researcher in the Science corpus: 9 papers; trusts 0 researchers and is trusted by 2 researchers here, as inferred from the citation graph.

Who trusts J. Schiller overall

  1. M. Reck
  2. William Pao
  3. B. Chan

Papers from J. Schiller's perspective

Ordered by how strongly the researchers J. Schiller trusts endorse each paper. Same corpus, a different order for every researcher.

  1. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. (Journal of Clinical Oncology)
  2. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. (New England Journal of Medicine)
  3. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. (Journal of the American Medical Association (JAMA))
  4. Anticancer drugs: To the rescue? (Nature reviews. Drug discovery)
  5. SEER Cancer Statistics Review, 1975-2003
  6. Cancer burden in the year 2000. The global picture. (European Journal of Cancer)
  7. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. (Journal of Clinical Oncology)
  8. KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib (PLoS Medicine)
  9. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. (Clinical Cancer Research)
  10. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice (Nature)

Their papers